ArticleAntimicrobial agents and chemotherapy1998
Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages.
Article in Antimicrobial agents and chemotherapy, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 113 citations in OpenAlex.
- AI-Driven Secondary Immunomodulatory Effects of Conventional Drugs on Patient-Derived Macrophages.International journal of molecular sciences · 2026Article
- Biotinylated Photocleavable Semiconductor Colloidal Quantum Dot Supraparticle Microlaser.ACS applied nano materials · 2024Article
- Mannosylated Systems for Targeted Delivery of Antibacterial Drugs to Activated Macrophages.International journal of molecular sciences · 2022Article
- Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery.Pharmaceutics · 2019Article
- Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes.Pharmaceutics · 2019Article
- Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.Current drug delivery · 2019Review
- Chemotherapeutic drug targeting to lungs by way of microspheres after intravenous administration.Drug design, development and therapy · 2018Article
- 25-Hydroxyvitamin D(3)-loaded PLA microspheres: in vitro characterization and application in diabetic periodontitis models.AAPS PharmSciTech · 2013Article
- Drug delivery systems: An updated review.International journal of pharmaceutical investigation · 2012Article
- Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.The Yale journal of biology and medicine · 2011Review
- Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies.International journal of molecular sciences · 2011Article
- Current development and future prospects in chemotherapy of tuberculosis.Respirology (Carlton, Vic.) · 2010Review
- Novel drug delivery systems: desired feat for tuberculosis.Journal of advanced pharmaceutical technology & research · 2010Article
- Slow release formulations of inhaled rifampin.The AAPS journal · 2008Article
- Formation of inhalable rifampicin-poly(L-lactide) microparticles by supercritical anti-solvent process.AAPS PharmSciTech · 2008Article
- Tuberculosis chemotherapy: current drug delivery approaches.Respiratory research · 2006Review
- The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.American journal of respiratory and critical care medicine · 2005Review
- Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.Pharmaceutical research · 2001Article
- Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.Pharmaceutical research · 2001Article
- Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.Antimicrobial agents and chemotherapy · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Microsphere technology was used to develop formulations of rifampin for targeted delivery to host macrophages. These formulations were prepared by using biocompatible polymeric excipients of lactide and glycolide copolymers. Release characteristics were examined in vitro and also in two monocytic cell lines, the murine J774 and the human Mono Mac 6 cell lines. Bioassay assessment of cell culture supernatants from monocyte cell lines showed release of bioactive rifampin during a 7-day experimental period. Treatment of Mycobacterium tuberculosis H37Rv-infected monocyte cell lines with rifampin-loaded microspheres resulted in a significant decrease in numbers of CFU at 7 days following initial infection, even though only 8% of the microsphere-loaded rifampin was released. The levels of rifampin released from microsphere formulations within monocytes were more effective at reducing M. tuberculosis intracellular growth than equivalent doses of rifampin given as a free drug. These results demonstrate that rifampin-loaded microspheres can be formulated for effective sustained and targeted delivery to host macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.